165 related articles for article (PubMed ID: 19895663)
1. The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Buck K; Voehringer P; Ferger B
J Neurochem; 2010 Jan; 112(2):444-52. PubMed ID: 19895663
[TBL] [Abstract][Full Text] [Related]
2. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
3. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
4. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Savola JM; Hill M; Engstrom M; Merivuori H; Wurster S; McGuire SG; Fox SH; Crossman AR; Brotchie JM
Mov Disord; 2003 Aug; 18(8):872-83. PubMed ID: 12889076
[TBL] [Abstract][Full Text] [Related]
5. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
7. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Cenci MA
Amino Acids; 2002; 23(1-3):105-9. PubMed ID: 12373525
[TBL] [Abstract][Full Text] [Related]
8. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
Lundblad M; Picconi B; Lindgren H; Cenci MA
Neurobiol Dis; 2004 Jun; 16(1):110-23. PubMed ID: 15207268
[TBL] [Abstract][Full Text] [Related]
9. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
[TBL] [Abstract][Full Text] [Related]
11. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
Tomiyama M; Kimura T; Maeda T; Kannari K; Matsunaga M; Baba M
Neurosci Res; 2005 Jun; 52(2):185-94. PubMed ID: 15893579
[TBL] [Abstract][Full Text] [Related]
12. Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours.
Lane EL; Cheetham SC; Jenner P
Eur J Neurosci; 2005 Jan; 21(1):179-86. PubMed ID: 15654855
[TBL] [Abstract][Full Text] [Related]
13. Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats.
Smith AD; Kozlowski DA; Bohn MC; Zigmond MJ
Exp Neurol; 2005 Jun; 193(2):420-6. PubMed ID: 15869944
[TBL] [Abstract][Full Text] [Related]
14. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.
Cenci MA; Lee CS; Björklund A
Eur J Neurosci; 1998 Aug; 10(8):2694-706. PubMed ID: 9767399
[TBL] [Abstract][Full Text] [Related]
15. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
Johansson PA; Andersson M; Andersson KE; Cenci MA
Neurobiol Dis; 2001 Apr; 8(2):220-39. PubMed ID: 11300719
[TBL] [Abstract][Full Text] [Related]
16. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
Smith LA; Tel BC; Jackson MJ; Hansard MJ; Braceras R; Bonhomme C; Chezaubernard C; Del Signore S; Rose S; Jenner P
Mov Disord; 2002 Sep; 17(5):887-901. PubMed ID: 12360537
[TBL] [Abstract][Full Text] [Related]
17. Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.
Bhide N; Lindenbach D; Barnum CJ; George JA; Surrena MA; Bishop C
J Neurochem; 2015 Jul; 134(2):222-32. PubMed ID: 25866285
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.
Carta AR; Pinna A; Cauli O; Morelli M
Synapse; 2002 Jun; 44(3):166-74. PubMed ID: 11954048
[TBL] [Abstract][Full Text] [Related]
19. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
Henry B; Fox SH; Peggs D; Crossman AR; Brotchie JM
Mov Disord; 1999 Sep; 14(5):744-53. PubMed ID: 10495035
[TBL] [Abstract][Full Text] [Related]
20. Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats.
Gołembiowska K; Dziubina A
Neuropharmacology; 2004 Sep; 47(3):414-26. PubMed ID: 15275831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
